Supplemental Material

A. VP8*-P[4], 159 amino acid (aa) residues

LDGPYQPTTFKPPNDYWLLISSNTDGVVYESTNNSDFWTAVIAVEPHVSQTNRQYVLFGENKQFNVENSSDKWKF-
FEMFKGSSQSDFSNRRTLTSNNRLVGMLKYGGRVWTFHGETPRATTDSSNTADLNNISIIIHSEFYIIPRSQESKCNEY-
INNGL

B. VP8*-P[6], 159 aa residues

LDGPYQPTNFKPPNDYWILLNPTNQQVVLEGTNNTDIWVALLLVEPNVTNQSRQYTLFGEMKQITVENNTNKWKF-
FEMFRSNVSAEFQHKRTLTSDTKLAGFMKFYNSVWTFHGETPHATTDYSSTSNLSEVQTVIHVEFYIIPRSQESKCSEY-
INTGL

C. VP8*-P[8], 159 aa residues

LDGPYQPTTFTPPTDYWILINSNTNGVVYESTNNSDFWTAVIAVEPHVDPVDRQYNVFGENKQFNVRNDSDKWK-
FLEMFRGSSQNDFYNRRTLTSDTRLVGILKYGGRIWTFHGETPRATTDSSNTANLNGISITIHSEFYIIPRSQESKCNEY-
INNGL

D. VP5*, 232 aa residues

AQVNEDIIVSKTSLWKEMQYNRDIIIRFKFGNSIVKMGGLGYKWSEISYKAANYQYNYLRDGEQVTAHTTCSVNGVN-
NFSYNGGSLPTDFGISRYEVIKENSYVYVDYWDDSKAFRNMVYVRSLAANLNSVKCTGGSYDFSIPVGAWPVMNG-
GAVSLHFAGVTLSTQFTDFVSLNSLRFRFSLTVDEPSFSILRTRTVNLYGLPAANPNNGNEYYEISGRFSLISLVPTNDD

Supplement 1. Consensus amino acid sequences of antigens VP8* (three genotypes) and VP5* that were employed for "reverse translation" *in silico* with subsequent cloning of synthetic genes into a vector for expression in *Escherichia coli*. (A) VP8*-P[4], (B) VP8*-P[6], (C) VP8*-P[8], (D) VP5*.

 https://doi.org/10.7774/cevr.2021.10.2.123